RxDoctor Payments DataLook up a doctor →

Ray Kelley, MD

Family Medicine · Wasilla, AKNPI 1780654137

Payments from drug & device makers

$8,789in general payments, 2019–2025

Across 436 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$813
  • Novo Nordisk$570
  • Amgen$566
  • GSK$562
  • Astellas Pharma US Inc$527
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$8,785100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,789 in reported general payments places this provider in the 95th percentile of 334 family medicine providers in Alaska.

See all family medicine providers in Alaska

Medicare billing

Part B allowed, 2024
$230,352
Medicare patients
430
Services billed
2,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$78,974
EliquisApixaban59$75,366
FarxigaDapagliflozin Propanediol35$48,969
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$44,611
LinzessLinaclotide32$29,731
JardianceEmpagliflozin22$25,094
TrulicityDulaglutide12$21,021
XareltoRivaroxaban15$20,601
MyrbetriqMirabegron20$19,942
Breo ElliptaFluticasone/Vilanterol12$12,998
TradjentaLinagliptin14$6,643
Xtampza ErOxycodone Myristate13$4,314
Venlafaxine Hcl ErVenlafaxine Hcl24$4,165
Lansoprazole24$4,130
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$570$78,97457 claims
PfizerEliquis$432$75,36659 claims
GSKTrelegy Ellipta, Breo Ellipta$562$57,60938 claims
AstraZenecaFarxiga$813$48,96935 claims
Boehringer IngelheimJardiance, Tradjenta$93$31,73836 claims
AbbVieLinzess, Synthroid$2,015$31,08254 claims
Lilly USA, LLCTrulicity$385$21,02112 claims
Johnson & JohnsonXarelto$112$20,60115 claims
Astellas Pharma US IncMyrbetriq$527$19,94220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 family medicine providers in Alaska.

Other family medicine in Wasilla

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →